## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)** OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 3, 2023

# **SCILEX HOLDING COMPANY**

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

001-39852 (Commission File Number)

92-1062542 (IRS Employer Identification No.)

960 San Antonio Road, Palo Alto, California, 94303 (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (650) 516-4310

(Former name or former address, if changed since last report)

	Trading Name of each exchange		
Securities registered pursuant to Section 12(b) of the Act			
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	SCLX	The Nasdaq Stock Market LLC
Warrants to purchase one share of common stock,	SCLXW	The Nasdaq Stock Market LLC
each at an exercise price of \$11.50 per share		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

#### Item 2.02. Results of Operations and Financial Condition.

Scilex Holding Company (the "Company") is providing certain preliminary unaudited financial results for the three months ended March 31, 2023, and as of March 31, 2023, based on currently available information. The Company's independent auditor has not reviewed or audited these preliminary estimated financial results. The Company's actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. The Company has not fully completed its review of these preliminary financial results for the three months ended March 31, 2023, and as of March 31, 2023.

The Company estimates that: ZTlido gross sales for the first quarter of 2023 were in the range of \$26.7 million to \$28.3 million, compared to \$18.4 million in the first quarter of 2022, representing growth in the range of 45% to 54%; net sales for the first quarter of 2023 were in the range of \$9.9 million to \$11.0 million, compared to net sales of \$6.8 million in the first quarter of 2022, representing growth in the range of 45% to 62%. Historically, sales for ZTlido are low during the first quarter of the year due to deductibles with managed healthcare plans.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number
Description

104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXRL).

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### SCILEX HOLDING COMPANY

By: /s/ Jaisim Shah

Name: Jaisim Shah

Title: Chief Executive Officer & President

Date: April 3, 2023